| Source: |
Escherichia coli |
| Molecular Weight: |
Approximately 10.5 kDa, a single non-glycosylated polypeptide chain consisting of an N-terminal Methionine and the mature rat Eotaxin-2. |
| AA Sequence: |
MPTGSVTIPS SCCVTFISKK IPVNRVISYQ LANGSICPKA GVIFITKKGH KICTDPKLPW VQKHIKNLDA KRNQPSEGAK ALGPKFVIQK LRGNSTKV |
| Purity: |
> 96% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Fully biologically active when compared to standard. The biologically active determined by a chemotaxis bioassay using human peripheral blood eosinophils is in a concentration of 50-250 ng/mL. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 µm filtered concentrated solution in 2 × PBS, pH7.4. |
| Endotoxin: |
Less than 1 EU/µg of rRtEotaxin-2/CCL24 as determined by LAL method. |
| Reconstitution: |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Synonyms: |
CK-beta-6, MPIF-2, Small-inducible Cytokine A24 |
| Background: |
CCL24, also known as MPIF-2, eotaxin-2, and Ckβ6, is a newly identified CC chemokine. This secreted protein is encoded by the CCL24 gene and produced by activated monocytes and T lymphocytes. CCL24 signals through the CCR3 receptor and exhibits chemotactic activity for resting T-lymphocytes and eosinophils, but not for monocytes and activated lymphocytes. There is a positive correlation between plasma levels of CCL24 and the morbidity rate of aspirin-exacerbated respiratory diseases, such as asthma. |
